Royalty Report: Medical, Pain, Delivery – Collection: 7524

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Medical
  • Pain
  • Delivery
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7524

License Grant
The Canadian Licensor grants to the Licensee, a subsidiary, the exclusive right to use the Protocol in the territory and for the use of Licensor know how and any of its trademarks.

Licensee shall have the right to enter into licensing, joint venture and acquisition Agreements with clinics that provide pain management services under the direction of physicians who are properly Licensed to practice medicine and qualified to treat patients using the Protocol in the territory; establish pharmacies that will be within or associated with clinics acquired by Licensor as permitted by the regulations enforced by the applicable governments within the territory; and take such steps that are deemed necessary to develop the business of pain management in the territory.

License Property
Licensor is the owner of a proprietary pain management system known as the Champion Pain Care Protocol.

The Protocol is a new, proprietary medical approach for the treatment and management of chronic pain which consists of the following personalized treatment plans;

o Physical examination by the attending doctor, blood testing and urine drug screening to:

o
provide accurate diagnoses of the type and source of pain;

o
establish baseline drug profiles;

o
monitor treatment progress; and

o
maintain post-treatment support.

o Education for patients about the specific nature of their chronic pain.

o On-going interaction to ensure and support patient adherence to beneficial behavioral changes such as keeping regular hours to enhance sleep patterns.

o Relaxation training to reduce the effects or stress and anxiety which can aggravate pain.

o Specific amino acids and other dietary supplements to restore and maintain normal brain chemistry.

o Reduction of cellular inflammation through:

o
patient pain diary and tracking of food intake and activities;

o
identification of pain triggers and food sensitivities in the diet; and

o
proper nutrition to eliminate problem foods and provide better nutrition.

o Reduction of joint inflammation through:

o
dietary changes;

o
topical medications; and

o
light exercise regimens.

o Day and night time regimens to promote restorative sleep.

o Use electrotherapy stimulation (“CES”) to promote production and release of endorphins (Han et al., 1991; Han, 2004).

o Topical medications for pain relief.

o On-going counseling, telephone and on-line support and regular checkups to:

o
review progress and maintain flexible, individualized programs;

o
allow changes in the treatment protocols to achieve optimal results; and

o
promote continuing patient compliance and contact.

IPSCIO Record ID: 4665

License Grant
The Canadian Licensor hereby grants to Licensee, subsidiary, for the term of this Agreement, the exclusive right to use the Protocol in the Territory and for the Permitted Uses. The Permitted Uses shall mean any use of the Licensor know how and any of its trademarks.
License Property
Licensor is the owner of a proprietary pain management system known as the Champion Pain Care Protocol.
Field of Use
Licensee shall have the right to enter into licensing, joint venture and acquisition agreements with clinics that provide pain management services under the direction of physicians who are properly licensed to practice medicine and qualified to treat patients using the Protocol in the Territory; establish pharmacies that will be within or associated with clinics acquired by Licensor as permitted by the regulations enforced by the applicable governments within the Territory;  and take such steps that are deemed necessary to develop the business of pain management in the Territory.

IPSCIO Record ID: 166205

License Grant
Licensor grants an exclusive worldwide license, with tile right to sub-license, under Licensors Product Intellectual Property to make, have made, sell, or have sold, and otherwise commercialize, market and distribute the Product throughout the world.
License Property
Licensor has developed a proprietary drug delivery system, including drug infusion pumps, ports, catheters, programming systems and accessories.  The Product is a preservative-free injectable formulation or formulations of clonidine and all current or future analogs, modifications and improvements of clonidine.

The SynchroMed system is the only externally programmable, implantable, drug infusion system available today. Using telemetry, the clinician can program its pump to deliver precise doses of medication at specific times to provide optimum therapy for each patient. It is widely used with morphine sulfate to block pain signals traveling to the brain and is also used to treat severe spasticity associated with multiple sclerosis, spinal cord injury, cerebral palsy, and traumatic brain injury. Clinical trials are expected to be initiated in 1998.

Field of Use
The Licensee will test the use of clonidine, delivered directly to the spinal fluid by the Medtronic SynchroMed(R) implantable drug infusion system, in the treatment of chronic intractable pain. Intractable pain is typically defined as constant, long-term pain that is not manageable without intervention. Clonidine delivered intrathecally (inside the sheath that surrounds the spinal cord) may be effective in patients with pain who no longer experience adequate relief with intrathecal morphine. These patients, if not already using a SynchroMed system, will require its implant to deliver intrathecal clonidine.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.